Contributions
Abstract: EP1279
Type: ePoster
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
Objective: To evaluate the possible correlation of the presence in the serum and/or CSF of Tau protein, CXCL13 and Neurofilaments, with the risk of developing Clinically Definite MS, following an initial clinically isolated syndrome CIS.
Design and methods: 29 patients with CIS from our MS Centre at Hadassah were included in a prospective study in addition to 23 controls and followed up for 1-5 years. The primary end point of the study was the conversion from CIS to CDMS. We compared the percentage of patients who were positive for 1 or more of the suggested biomarkers in their sera/CSF who developed CDMS after 1-5 years of follow up, with the percentage of those who were negative for the same biomarkers. A secondary end point was to establish a quantitative correlation between the levels of the biomarkers in the serum and/or CSF and the probability of conversion to CDMS. ELISA was used for measurement of the serum and CSF levels of the fore mentioned biomarkers.
Results: During the follow up period, 20 patients were finally diagnosed with CDMS and 9 patients remained as CIS with similar gender distribution between the two groups. A significant difference between the values of 2 of the tested biomarkers (CXCL13 and neurofilaments) in the sera of patients who converted to CDMS as compared to patients who remained CIS throughout the study period. 75% of patients and 70% of patients who were diagnosed as CDMS tested positive for CXCL13 or NFL in their serum vs only 1 out of 9 (for either CXCL13 or NFL) who remained as CIS (P value 0.0009 with a median value of 9 pg/ml for CIS patients and a median value of 48.5 pg/ml for CDMS patients, risk ratio 6.75, odds ratio 24 from CXCL13; median level of NFL 622 pg/ml for CIS vs 1119 pg/ml for CDMS patients).Double positivity was found to have a strong negative predictive value as zero percent of the CIS patients were double positive, and 10 out of 20 CDMS patients (50%) were found to be positive for both CXCL13 and NFL (95% confidence interval, risk ratio of 2 and odds ration approaching infinity value). The values in the CSF were insignificant which could be attributed to the long period of preservation of the CSF or could signify the need of more sensitive methods for their measurement. Tau levels were not significant neither in the CSF nor in the sera of the tested population.
Conclusions: CXCL13 and neurofilaments in the serum of patients with CIS, may represent significant predictive biomarkers for conversion to CDMS
Disclosure:
Nour Eddine Yaghmour: Nothing to disclose
Panayiota Petrou: Nothing to disclose
Ibrahim Kassis: Nothing to disclose
Michel Halimi: Nothing to disclose
Dimitrios Karussis: Nothing to disclose
Abstract: EP1279
Type: ePoster
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
Objective: To evaluate the possible correlation of the presence in the serum and/or CSF of Tau protein, CXCL13 and Neurofilaments, with the risk of developing Clinically Definite MS, following an initial clinically isolated syndrome CIS.
Design and methods: 29 patients with CIS from our MS Centre at Hadassah were included in a prospective study in addition to 23 controls and followed up for 1-5 years. The primary end point of the study was the conversion from CIS to CDMS. We compared the percentage of patients who were positive for 1 or more of the suggested biomarkers in their sera/CSF who developed CDMS after 1-5 years of follow up, with the percentage of those who were negative for the same biomarkers. A secondary end point was to establish a quantitative correlation between the levels of the biomarkers in the serum and/or CSF and the probability of conversion to CDMS. ELISA was used for measurement of the serum and CSF levels of the fore mentioned biomarkers.
Results: During the follow up period, 20 patients were finally diagnosed with CDMS and 9 patients remained as CIS with similar gender distribution between the two groups. A significant difference between the values of 2 of the tested biomarkers (CXCL13 and neurofilaments) in the sera of patients who converted to CDMS as compared to patients who remained CIS throughout the study period. 75% of patients and 70% of patients who were diagnosed as CDMS tested positive for CXCL13 or NFL in their serum vs only 1 out of 9 (for either CXCL13 or NFL) who remained as CIS (P value 0.0009 with a median value of 9 pg/ml for CIS patients and a median value of 48.5 pg/ml for CDMS patients, risk ratio 6.75, odds ratio 24 from CXCL13; median level of NFL 622 pg/ml for CIS vs 1119 pg/ml for CDMS patients).Double positivity was found to have a strong negative predictive value as zero percent of the CIS patients were double positive, and 10 out of 20 CDMS patients (50%) were found to be positive for both CXCL13 and NFL (95% confidence interval, risk ratio of 2 and odds ration approaching infinity value). The values in the CSF were insignificant which could be attributed to the long period of preservation of the CSF or could signify the need of more sensitive methods for their measurement. Tau levels were not significant neither in the CSF nor in the sera of the tested population.
Conclusions: CXCL13 and neurofilaments in the serum of patients with CIS, may represent significant predictive biomarkers for conversion to CDMS
Disclosure:
Nour Eddine Yaghmour: Nothing to disclose
Panayiota Petrou: Nothing to disclose
Ibrahim Kassis: Nothing to disclose
Michel Halimi: Nothing to disclose
Dimitrios Karussis: Nothing to disclose